PML News

Tysabri Re-Approved by FDA Despite Life Threatening Side Effects

At a glance:

Sales of the Multiple Sclerosis drug Tysabri were suspended in February of 2005 when a number of patients taking the drug, along with a drug called Avonex developed progressive multifocal leukoencephalopathy a life threatening condition. Although the sales of Tysabri were suspended, the FDA convened an independent advisory panel that has unanimously re-approved the drug for distribution. This action has caused consternation among many who feel the FDA is too closely tied to the pharmaceutical industry and is making decisions based on profits rather than on the wellbeing of patients.

Tysabri Waltzes through FDA Advisory Panel by 12-0 Vote

Newsinferno.com - 3/9/2006 5:07 PM

When sales of Tysabri were suspended on February 28, 2005, many critics of the highly controversial MS drug, with potentially fatal side-effects, hoped that would end the saga of a medication that many experts believed should never have been approved in the first place. That, however, was only the beginning of the story.
 
Much had been written about Tysabri before the panel met this week and most of that was negative. In fact, the claims contained in law suits, medical journal articles, and collateral research since 1991 indicated (quite strongly) that the drug should probably have neve

 
· Read The Full PML Article From Newsinferno.com -->

· Read All PML News Stories -->

Comments On PML News Articles:


No Current Comments
Posted by Admin on 3/20/2006

There are no current comments. Why not post one?

Leave a Comment:

Once you click the 'Save Comment' button, you will receive a verification email from our website. Be sure to change any spam settings to allow webmaster@lawsuitsearch.com as a trusted sender.
 
If you are already a member, you can Sign In Here.
 
You can create your own FREE user account that you can use to participate in our message boards, blogs, newsletters and other community activities such as this one. To get your FREE user account, click here.

Email Address:

Your Name:

Message Title:

Message: